WO2005060520A3 - ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF - Google Patents
ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF Download PDFInfo
- Publication number
- WO2005060520A3 WO2005060520A3 PCT/US2004/039750 US2004039750W WO2005060520A3 WO 2005060520 A3 WO2005060520 A3 WO 2005060520A3 US 2004039750 W US2004039750 W US 2004039750W WO 2005060520 A3 WO2005060520 A3 WO 2005060520A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cov
- sars
- methods
- coronavirus
- antibodies against
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 241000711573 Coronaviridae Species 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2004800408778A CN1914226B (en) | 2003-11-25 | 2004-11-24 | Antibodies against SARS-COV and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52484003P | 2003-11-25 | 2003-11-25 | |
US60/524,840 | 2003-11-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005060520A2 WO2005060520A2 (en) | 2005-07-07 |
WO2005060520A3 true WO2005060520A3 (en) | 2005-10-20 |
Family
ID=34710040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/039750 WO2005060520A2 (en) | 2003-11-25 | 2004-11-24 | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
Country Status (3)
Country | Link |
---|---|
US (1) | US7750123B2 (en) |
CN (1) | CN1914226B (en) |
WO (1) | WO2005060520A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7116256B1 (en) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629443B2 (en) * | 2004-06-02 | 2009-12-08 | New York Blood Center, Inc. | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus |
NZ553701A (en) * | 2004-11-11 | 2009-12-24 | Crucell Holland Bv | Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV |
WO2006095180A2 (en) * | 2005-03-10 | 2006-09-14 | Ultra Biotech Limited | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
WO2007044695A2 (en) * | 2005-10-07 | 2007-04-19 | Dana-Farber Cancer Institute | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
JP2009537143A (en) * | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Antibodies against SARS coronavirus |
SI2395018T1 (en) | 2006-06-06 | 2016-06-30 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
NZ586611A (en) * | 2007-12-06 | 2012-09-28 | Dana Farber Cancer Inst Inc | Antibodies against influenza virus and methods of use thereof |
CN104628848B (en) * | 2013-11-14 | 2018-01-23 | 清华大学 | Monoclonal antibody MERS 27 and its encoding gene and application |
JO3701B1 (en) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
CN105859837B (en) * | 2014-10-22 | 2020-11-20 | 台北医学大学 | Cholesteryl ester transfer protein antigen peptide and fusion protein, composition and application thereof |
WO2018071913A2 (en) | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Modular tetrameric bispecific antibody platform |
US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11339190B2 (en) * | 2020-04-21 | 2022-05-24 | Rush University Medical Center | Peptides for the treatment of covid-19 |
AU2021220847A1 (en) * | 2020-02-11 | 2022-09-01 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) |
CN111686253A (en) * | 2020-02-20 | 2020-09-22 | 田中民 | A new method for preventing and killing coronavirus |
RS64645B1 (en) | 2020-02-26 | 2023-10-31 | Vir Biotechnology Inc | Antibodies against sars-cov-2 |
CN111273016B (en) * | 2020-02-26 | 2021-06-15 | 浙江诺迦生物科技有限公司 | Kit for rapidly detecting coronavirus based on S protein ligand and ACE2 receptor competition chromatography |
CN111398581B (en) * | 2020-02-27 | 2021-05-25 | 四川省医学科学院·四川省人民医院 | COVID-19 rapid diagnosis kit and preparation method thereof |
CN111285933A (en) * | 2020-03-09 | 2020-06-16 | 四川省人民医院 | Novel coronavirus antigen colloidal gold diagnostic kit |
CN111239394B (en) * | 2020-03-09 | 2021-05-18 | 四川省医学科学院·四川省人民医院 | Novel coronavirus antibody rapid detection kit based on mixed antigens |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
CN111366735B (en) * | 2020-03-20 | 2021-07-13 | 广州市康润生物科技有限公司 | Novel early stage coronavirus screening method |
CN111366734B (en) * | 2020-03-20 | 2021-07-13 | 广州市康润生物科技有限公司 | Method for screening new coronavirus through double indexes and predicting severe pneumonia |
CN115279785A (en) * | 2020-03-25 | 2022-11-01 | 神州细胞工程有限公司 | Preparation and application of SARS-CoV-2 and SARS-CoV cross neutralizing antibody |
WO2021195326A1 (en) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
CN115916343A (en) * | 2020-03-26 | 2023-04-04 | 普罗维克图斯药品技术公司 | New use of halogenated xanthenes in oncology and virology |
EP4126034A1 (en) * | 2020-03-27 | 2023-02-08 | Beech Tree Labs Inc. | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof |
WO2021201679A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting coronaviruses |
WO2021202893A1 (en) * | 2020-04-03 | 2021-10-07 | Nonigenex, Inc. | Detecting adaptive immunity to coronavirus |
RU2728939C1 (en) * | 2020-04-16 | 2020-08-03 | Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) | Using dalargin for producing agents for treating covid-19 coronavirus infection |
US20210388065A1 (en) * | 2020-04-15 | 2021-12-16 | Active Motif Shanghai Limited | Antibodies to sars-coronavirus (covid-19) s1 spike protein |
CN111505286A (en) * | 2020-04-28 | 2020-08-07 | 郑州伊美诺生物技术有限公司 | Novel coronavirus specific antibody double-antigen sandwich E L ISA detection kit and preparation method thereof |
WO2021224803A1 (en) * | 2020-05-05 | 2021-11-11 | Nono Inc. | Peptide inhibitors of sarsr-cov infection |
US11789020B2 (en) | 2020-05-12 | 2023-10-17 | Sapphire Biotech, Inc. | Neutralizing antibody testing and treatment |
US11066712B1 (en) * | 2020-05-18 | 2021-07-20 | Bret T. Barnhizer | Rapid viral assay |
WO2021237057A1 (en) * | 2020-05-21 | 2021-11-25 | David Wong | Sars-cov-2 (covid-19) antibody test on saliva and blood using efirm technology |
CN115708418A (en) * | 2020-05-28 | 2023-02-21 | 南京蓬勃生物科技有限公司 | SARS-CoV-2 pseudovirus and method for detecting sample neutralizing SARS-CoV-2 ability |
CN112180101A (en) * | 2020-06-01 | 2021-01-05 | 北京松果天目健康管理有限公司 | Kit for detecting abundance of ACE2 receptor and detection method |
CA3188993A1 (en) * | 2020-06-09 | 2021-12-16 | The Wistar Institute Of Anatomy And Biology | Dna encoded antibodies for use against sars-cov-2 |
CN111718411B (en) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 1F2 for resisting SARS-CoV-2 |
CN111690059B (en) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 1D7 for resisting SARS-CoV-2 |
EP4171606A1 (en) * | 2020-06-26 | 2023-05-03 | Prothione, LLC | Compositions and methods for the treatment of covid-19 |
US20220008380A1 (en) * | 2020-07-07 | 2022-01-13 | Ut-Battelle, Llc | Methods of treating covid-19 pathogenesis |
AU2021209282B2 (en) | 2020-09-04 | 2022-06-02 | Newsoara Biopharma Co., Ltd. | Anti-Sars-Cov-2 Neutralizing Antibodies |
WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
EP3970798A1 (en) * | 2020-09-18 | 2022-03-23 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Sars-cov-2-nanobodies |
CN114252417A (en) * | 2020-09-23 | 2022-03-29 | 中国科学院大连化学物理研究所 | Method for dynamically observing interaction between ACE2 and novel coronavirus RBD in real time |
CN112626099A (en) * | 2020-09-29 | 2021-04-09 | 清华大学 | Method for fermenting and expressing angiotensin converting enzyme 2 by using prokaryotic cells |
CN112409488B (en) * | 2020-10-23 | 2022-07-01 | 中国科学院上海药物研究所 | Monoclonal antibody aiming at various coronaviruses and application |
US11105804B1 (en) * | 2020-12-14 | 2021-08-31 | Raybiotech Life, Inc. | COVID-19 spike-ACE2 binding assay for drug and antibody screening |
AU2021209287B1 (en) | 2021-01-19 | 2022-03-24 | Newsoara Biopharma Co., Ltd. | Expression Vector for Anti-Sars-Cov-2 Neutralizing Antibodies |
EP4281468A1 (en) * | 2021-01-22 | 2023-11-29 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Monoclonal antibodies against corovaviruses and uses thereof |
CN112980885B (en) * | 2021-03-18 | 2022-04-15 | 恒翼生物医药科技(上海)有限公司 | Expression vector of anti-SARS-COV-2 neutralizing antibody |
US20220326240A1 (en) * | 2021-04-09 | 2022-10-13 | Bio-Rad Laboratories, Inc. | Immunoassay for sars-cov-2 and materials therefor |
WO2022241415A1 (en) * | 2021-05-11 | 2022-11-17 | Yale University | Methods for monoclonal antibody generation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085650A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) |
WO2005027963A2 (en) * | 2003-09-15 | 2005-03-31 | The United States Of America As Represented By Thesecretary Of Health And Human Services, Nih | METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5030719A (en) * | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ES2096590T3 (en) | 1989-06-29 | 1997-03-16 | Medarex Inc | BI-SPECIFIC REAGENTS FOR AIDS THERAPY. |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ATE139258T1 (en) * | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
EP0546073B1 (en) * | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
USRE37525E1 (en) * | 1991-05-01 | 2002-01-22 | Henry M. Jackson Foundation | Method for treating infectious respiratory diseases |
EP0583356B1 (en) * | 1991-05-01 | 2002-07-31 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5233409A (en) * | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
AU686113B2 (en) * | 1992-09-16 | 1998-02-05 | Scripps Research Institute, The | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
EP0689455A4 (en) * | 1993-03-11 | 1997-07-23 | Univ Southern California | Therapeutic strategies for immunoinfective cluster virus infections |
JPH09505466A (en) * | 1993-10-19 | 1997-06-03 | ザ スクリップス リサーチ インスティテュート | Synthetic human monoclonal neutralizing antibody against human immunodeficiency virus |
AU1866895A (en) * | 1994-01-04 | 1995-08-01 | Scripps Research Institute, The | Human monoclonal antibodies to herpes simplex virus and methods therefor |
CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
JP4312259B2 (en) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | Human antibodies derived from immunized XenoMouse |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6538114B1 (en) * | 1996-04-19 | 2003-03-25 | Karolina Innovations Ab | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen |
US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6063905A (en) * | 1997-01-07 | 2000-05-16 | Board Of Regents, The University Of Texas System | Recombinant human IGA-J. chain dimer |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
US20050113298A1 (en) * | 2003-09-15 | 2005-05-26 | The Brigham And Women's Hospital, Inc. | Receptor binding peptides derived from the SARS S protein |
-
2004
- 2004-11-24 WO PCT/US2004/039750 patent/WO2005060520A2/en active Application Filing
- 2004-11-24 CN CN2004800408778A patent/CN1914226B/en not_active Expired - Fee Related
- 2004-11-24 US US10/997,201 patent/US7750123B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004085650A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) |
WO2005027963A2 (en) * | 2003-09-15 | 2005-03-31 | The United States Of America As Represented By Thesecretary Of Health And Human Services, Nih | METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV |
Non-Patent Citations (7)
Title |
---|
BONAVIA AURELIO ET AL: "Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E.", JOURNAL OF VIROLOGY, vol. 77, no. 4, February 2003 (2003-02-01), pages 2530 - 2538, XP002342003, ISSN: 0022-538X * |
HARRISON J L ET AL: "SCREENING OF PHAGE ANTIBODY LIBRARIES", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 267, 1996, pages 81 - 109, XP002944558, ISSN: 0076-6879 * |
HOLMES K V: "SARS coronavirus: a new challenge for prevention and therapy", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 111, no. 11, June 2003 (2003-06-01), pages 1605 - 1609, XP002981747, ISSN: 0021-9738 * |
KUBO H ET AL: "Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein.", JOURNAL OF VIROLOGY. SEP 1994, vol. 68, no. 9, September 1994 (1994-09-01), pages 5403 - 5410, XP009052918, ISSN: 0022-538X * |
LI J ET AL: "THE STRUCTURAL CHARACTERIZATION AND ANTIGENICITY OF THE S PROTEIN OF SARS-COV", GENOMICS PROTEOMICS AND BIOINFORMATICS, BEIJING GENOMICS INSTITUTE, BEIJING, CN, vol. 1, no. 2, May 2003 (2003-05-01), pages 108 - 117, XP008048300, ISSN: 1672-0229 * |
LI WENHUI ET AL: "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.", NATURE. 27 NOV 2003, vol. 426, no. 6965, 27 November 2003 (2003-11-27), pages 450 - 454, XP002342002, ISSN: 1476-4687 * |
SUI JIANHUA ET AL: "Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 101, no. 8, 24 February 2004 (2004-02-24), pages 2536 - 2541, XP002332534, ISSN: 0027-8424 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7116256B1 (en) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-SARS-COV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
JP7411029B2 (en) | 2020-04-02 | 2024-01-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-SARS-COV-2-spike glycoprotein antibody and antigen-binding fragment |
Also Published As
Publication number | Publication date |
---|---|
CN1914226B (en) | 2012-02-01 |
CN1914226A (en) | 2007-02-14 |
WO2005060520A2 (en) | 2005-07-07 |
US7750123B2 (en) | 2010-07-06 |
US20050249739A1 (en) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005060520A3 (en) | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF | |
WO2007044695A3 (en) | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF | |
HK1074634A1 (en) | Internalizing antibodies specific for the raag10 cell surface target | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
DE602004029399D1 (en) | ||
WO2005121179A3 (en) | Transferrin receptor antibodies | |
WO2005051178A3 (en) | Marker for neuromyelitis optica | |
WO2006125229A3 (en) | Use of tnf inhibitor for treatment of erosive polyarthritis | |
WO2006099698A3 (en) | Novel anti-plgf antibody | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
WO2007092433A3 (en) | Osteoporosis associated markers and methods of use thereof | |
WO2003002717A3 (en) | Biological activity of ak155 | |
WO2007073497A3 (en) | Calcium channel antagonists | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
WO2005115453A3 (en) | Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
WO2003024388A3 (en) | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma | |
WO2006105081A3 (en) | Pharmacokinetically improved compounds | |
WO2006083852A3 (en) | Luca2 and antibodies that bind thereto | |
TW200714716A (en) | Method | |
WO2008082651A3 (en) | Dual-specific il-1a/ il-1b antibodies | |
WO2006076584A3 (en) | Kid31 and antibodies that bind thereto | |
WO2006096487A3 (en) | Methods and compositions for modulating tweak and fn14 activity | |
WO2003055917A3 (en) | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours | |
WO2004067570A3 (en) | Prostate cancer diagnosis and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040877.8 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |